These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19362985)

  • 21. Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
    Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
    Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Jia X; Melhem M; Moreau AS; Ngo HT; Runnels J; Azab A; Azab F; Burwick N; Farag M; Treon SP; Palladino MA; Hideshima T; Chauhan D; Anderson KC; Ghobrial IM
    Blood; 2008 May; 111(9):4752-63. PubMed ID: 18316628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
    Roccaro AM; Ghobrial IM; Blotta S; Treon SP; Malagola M; Anderson KC; Richardson PG; Russo D
    Biologics; 2008 Sep; 2(3):419-31. PubMed ID: 19707373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel treatment regimens for Waldenström's macroglobulinemia.
    García-Sanz R; Ocio EM
    Expert Rev Hematol; 2010 Jun; 3(3):339-50. PubMed ID: 21082984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M
    Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future directions in immunomodulatory therapy.
    Lonial S
    Med Oncol; 2010 Jun; 27 Suppl 1():S62-6. PubMed ID: 20012563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitors in lung cancer.
    Scagliotti G
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
    Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.